Doctiplus - We are allways here!
Dementia & Alzheimer's
Weekly Report
- 10 new clinical trials registered across 6 countries.
- 943 trials actively recruiting patients worldwide.
- Notable trial: Visual Hallucinations in Lewy Body Diseases (234 patients).
- 1,959 new research papers published.
- Drug safety: Most reported effect across tracked medications (donepezil, memantine, rivastigmine, galantamine, lecanemab) was Death.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Dementia & Alzheimer's. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
10 trials registered for Dementia & Alzheimer's. Each links to its full record on ClinicalTrials.gov.
| # | Trial ↓ | Phase ↕ | Status ↕ | Enrollment ↕ | Country ↕ |
|---|---|---|---|---|---|
| 01 | The Effectiveness of a Caregiver-Based Multicomponent Intervention to Prevent Pressure Ulcers in Home-Cared-For Individuals With Dementia Dementia & Alzheimer's · Manisa Celal Bayar University (NCT07843888) | Other | Not Yet Recruiting | 120 | N/A |
| 02 | Rhythmic Entrainment and Alertness in Lewy Body Dementia Dementia & Alzheimer's · Johns Hopkins University (NCT07846189) | Other | Not Yet Recruiting | 30 | N/A |
| 03 | Neuroprotective Effects of Oleanolic Acid and Erythrodiol in Prodromal Alzheimer's Disease Dementia & Alzheimer's · Spanish National Research Council (NCT07847944) | Other | Not Yet Recruiting | 120 | Spain |
| 04 | [11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction Dementia & Alzheimer's · Stony Brook University (NCT07856043) | Phase 1 | Not Yet Recruiting | 18 | United States |
| 05 | ACT for Dementia Caregivers: Evaluating Psychological Flexibility as the Mechanism to Improve Psychological Distress Dementia & Alzheimer's · Utah State University (NCT07845032) | Other | Recruiting | 120 | United States |
| 06 | Choose Myself (Before) Losing Myself Dementia & Alzheimer's · The Cleveland Clinic (NCT07846566) | Other | Not Yet Recruiting | 25 | United States |
| 07 | Visual Hallucinations in Lewy Body Diseases Dementia & Alzheimer's · NYU Langone Health (NCT07849413) | Other | Recruiting | 234 | United States |
| 08 | Impact of Social Support Through Personalized Visits on Behavioral Symptoms in Residential Care Dementia & Alzheimer's · University of South Alabama (NCT07844980) | Other | Completed | 33 | United States |
| 09 | A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) Dementia & Alzheimer's · Eli Lilly and Company (NCT07843459) | Phase 1 | Not Yet Recruiting | 111 | United States |
| 10 | Restoring Cervical Lymphatic Drainage in Alzheimer's Disease Dementia & Alzheimer's · University of Siena (NCT07854327) | Other | Recruiting | 5 | Italy |
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Dementia & Alzheimer's. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| donepezil | Death | 208 |
| memantine | Death | 129 |
| rivastigmine | Death | 292 |
| galantamine | Fall | 32 |
| lecanemab | Amyloid Related Imaging Abnormality-oedema/effusion | 202 |
Recalls & safety notices
FDA drug recall notices for medications related to Dementia & Alzheimer's. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Dementia & Alzheimer's, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
Treating co-occurring alcohol use disorder and major depressive disorder: A systematic review of combination and multimodal pharmacotherapy.
View abstractBACKGROUND AND OBJECTIVES: Major depressive disorder (MDD) and alcohol use disorder (AUD) frequently co-occur and are associated with greater symptom severity and elevated suicide risk relative to either disorder alone, yet no pharmacological regimen is approved for the combined indication. This review systematically catalogs trials of combined and multimodal pharmacotherapy for comorbid AUD and MDD. METHODS: We searched PubMed/MEDLINE, Web of Science, and Google Scholar from inception through May 2024 for randomized or prospective open-label trials of combined pharmacotherapy, or single agents with dual-target activity, in adults with comorbid AUD and MDD. Seven trials (total N = 758) met inclusion criteria. RESULTS: Five trials tested combination regimens (naltrexone+acamprosate; naltrexone+disulfiram; naltrexone+sertraline; acamprosate+escitalopram; aripiprazole+escitalopram) and two tested single agents (vortioxetine; memantine vs. escitalopram). Naltrexone plus sertraline showed the strongest signal of dual benefit on drinking and depressive outcomes; acamprosate plus escitalopram was also promising, although based on a small pilot trial. Neither finding has been independently replicated, and the remaining regimens yielded mixed or modest results. DISCUSSION AND CONCLUSIONS: Converging dopaminergic, serotonergic, glutamatergic, opioidergic, and neuroimmune mechanisms support combined pharmacotherapy, but the evidence base remains thin, underpowered, and unreplicated. Available evidence and current integrated-care approaches favor concurrent rather than sequential treatment of AUD and MDD, although the evidence supporting specific pharmacological combinations remains limited. SCIENTIFIC SIGNIFICANCE: This is among the first reviews to integrate combination-pharmacotherapy trials with emerging multimodal single agents for comorbid AUD/MDD, and to map proposed mechanisms onto specific drug pairings, providing a framework for prioritizing future biologically stratified trials. |
The American journal on addictions | 2026 Oct 4 | PubMed |
| 02 |
Precision cognitive neurorehabilitation: dose, adaptivity, digital therapeutics and implementation.
View abstractINTRODUCTION: Cognitive deficits are determinants of long-term disability and socio-professional reintegration across neurological disorders, including stroke, traumatic brain injury, multiple sclerosis, and neurodegenerative diseases. Despite evidence supporting cognitive neurorehabilitation, its implementation remains heterogeneous, and therapeutic parameters are insufficiently defined. AREAS COVERED: The authors reviewed the published literature from PubMed and Google Scholar from 1 January 2015 to 30 June 2026, supplemented by seminal publications. Clinical trials, systematic reviews, meta-analyses, and observational and proof-of-concept studies were prioritized. This brief narrative review examines restorative and compensatory cognitive neurorehabilitation for deficits of attention, executive functions, language and disorders of consciousness in people after stroke and traumatic brain injury (TBI), older adults, and those with neurological and neurodegenerative conditions, including multiple sclerosis, Alzheimer's and Parkinson's disease. Emphasis is placed on dose, frequency, adaptivity, personalization, and digital and technology-assisted interventions. Methodological challenges include heterogeneity of protocols, limited use of active control conditions, insufficient long-term follow-up, and the gap between cognitive test improvements and meaningful effects on participation. EXPERT OPINION: Advancing cognitive neurorehabilitation requires precision-driven approaches integrating digital therapeutics with clinical frameworks. Large-scale pragmatic trials, meaningful endpoints, and implementation strategies across the continuum of care will be essential to transform cognitive neurorehabilitation into a component of neurological practice. |
Expert review of neurotherapeutics | 2026 Oct 4 | PubMed |
| 03 |
Therapeutic Impact of Snoezelen Environments on Emotional Outcomes and Pain in Long-Term Care Residents with and Without Dementia.
View abstractOBJECTIVES: Older adults living in long-term care facilities are at increased risk of reduced psychoemotional well-being. Snoezelen multisensory environments have been proposed as person-centered interventions, although evidence remains inconsistent. This study aimed to evaluate the effects of Snoezelen environments on biopsychosocial outcomes in older adults living in long-term care facilities with and without dementia. METHODS: A mixed-methods, quasi-experimental repeated-measures design was applied. Participants completed eight sessions over four weeks with a self-controlled comparison phase. Quantitative analyses examined pre-post intervention and pre-post session effects in physiological measures, pain perception, psychoemotional domains, functional status and quality-of-life outcomes. Data from focus groups with participants and professionals were analyzed thematically. RESULTS: Session-level analyses revealed improvements in emotional expression, psychoemotional outcomes, and pain perception following sessions. Qualitative findings supported these results. No pre-post intervention effects were observed. CONCLUSIONS: Snoezelen multisensory environments provide immediate psychoemotional benefits and pain reduction in older adults living in long-term care facilities with and without dementia. CLINICAL IMPLICATIONS: When implemented on demand or preventively, Snoezelen multisensory environments may serve as complementary, person-centered interventions in long-term care settings. |
Clinical gerontologist | 2026 Oct 4 | PubMed |
| 04 |
Should I drink water or wine? Impacts of online nutritional counseling on the alcohol consumption of elderly individuals with mild cognitive impairment : Secondary Data Analysis from the RCT "BrainFit-Nutrition".
View abstractBACKGROUND: People with mild cognitive impairment (MCI) have an increased health risk when they consume alcohol in comparison with people without cognitive impairment. Excessive alcohol consumption is an established modifiable risk factor that contributes to the risk of developing dementia. OBJECTIVE: Within a secondary data analysis of a 2 × 2 randomized controlled trial (RCT) - consisting of a computerized cognitive intervention and a nutrition counseling intervention -, we evaluated the impact of a nutritional counseling group (neither focusing solely on alcohol consumption) on alcohol consumption in people with MCI at a 12-months follow-up, identified predictors of changes in alcohol consumption, and determined whether women benefited in the same way as men. METHODS: One hundred eighty-nine (189) of 270 trial participants reported consuming alcohol at baseline and started one of the two nutritional counseling programs (ITT sample). Data were collected at a 12-months follow-up and imputed for n = 15 participants. Participants received either whole-food plant-based (WFPB) nutritional group counseling or nutritional group counseling based on the German Nutrition Society's (DGE) recommendations. Alcohol consumption was quantified with standard drinks (10 g alcohol)/day. Multiple linear regressions were used to identify potential predictors of reduction. P-values were corrected. RESULTS: The sample's average age was 70.6 years and nearly showed gender parity (52% female). Both interventions led to a significant reduction in alcohol consumption in people with MCI after 12 months (Cohen''''s d = .30 (WFPB); Cohen''''s d = .39 (DGE)). There were no significant differences in the change in consumption level over time between the nutritional counseling groups (p = .173). Women substantially reduced their alcohol consumption over time only in the DGE nutritional counseling group (Cohen''''s d = .33). In successful alcohol reducers (n = 84), higher baseline alcohol consumption (β = .670, p < .001), older age (β = .158, p = .035), and stricter adherence in the counseling group (β = .184, p = .017) were significant predictors of a greater reduction (F(7,76) = 18.539, p = .003). Higher cognitive functioning was a significant negative predictor of reduction (β = -.199, p = .009). CONCLUSION: In context of the lifestyle intervention of the BrainFit-Nutrition study, nutritional counseling for people with MCI was effective for reducing alcohol intake. Our results suggest focusing on younger people living with MCI as well as higher educated people, especially men, to optimize the potential of modifiable risk factors for dementia. However, gender differences exist. A gender-specific nutritional counseling program is advised in the light of the gender health gap. TRIAL REGISTRATION: ISRCTN10560738; registered 11/23/2021. |
BMC public health | 2026 Oct 3 | PubMed |
| 05 |
Interaction between mental health conditions and hip fracture on the 30-day risk of infection among older adults: a Danish matched cohort study.
View abstractPURPOSE: Infections are a frequent complication following hip fracture (HF) surgery. Although approximately 30% of patients undergoing HF surgery have a mental health condition, its potential interaction on the risk of post-operative infection remains uncertain. METHODS: Using Danish nationwide registries, we included a cohort of patients with HF aged ≥ 65 years operated during 2004-21 (n=100 335) and an age- and sex-matched comparison cohort from the general population without HF at the index date (n=498 943). Mental health conditions were identified using diagnosis codes F00-F48. Outcomes were hospital-treated infections (H-TIs) and hospital- or community-treated infections (HC-TIs) within 30 days after surgery. Cumulative incidence with 95% confidence intervals (CI) was estimated with death as competing risk. Interaction was assessed on an absolute and relative scale. RESULTS: The highest incidence of H-TIs was observed among patients with HF and mood disorders (18.1%, 95% CI: 17.3-19.0) and comparators with anxiety disorders (2%, 95% CI: 1.8-2.5). Among patients with HF, the highest incidence of HC-TIs was in those with dementia (43.0%, 95% CI: 42.2-43.9). Likewise, comparators with dementia had the highest incidence of HC-TIs (18.4%, 95% CI: 17.9-18.8). Across mental health condition categories, attributable fractions ranged from 1.1% to 32.3% for H-TIs and 10.8%-19.7% for HC-TIs. The strongest synergistic effect was observed in patients with psychoactive substance use for both H-TIs and HC-TIs. CONCLUSIONS: Patients with HF and mental health conditions are at higher risk of infection than comparators. Mental health conditions and HF interact synergistically, which increases the infection risk by more than 30%, highlighting the need for targeted treatment for patients with HF and mental health conditions. |
European geriatric medicine | 2026 Oct 3 | PubMed |
| 06 |
Association between BDNF methylation and expression of the NLRP3 inflammasome in the brain is disrupted in Alzheimer's disease.
View abstractActivation of the NLRP3 inflammasome pathway and dysfunction of brain-derived neurotrophic factor (BDNF) are both implicated in the pathogenesis of Alzheimer's disease (AD). While in vitro and in vivo models support these mechanisms, there is little research investigating their relationship in human brain tissue, and whether this relationship may be abnormal in the AD brain. Temporal cortex tissue taken post-mortem from AD patients and control subjects was analysed for expression of genes for the NLRP3 pathway (NLRP3, PYCARD, CASP1), the potassium channel THIK1 (KCNK13), and related pro-inflammatory cytokines (IL-1β, IL-18). BDNF mRNA expression and DNA methylation in the BDNF exon IV promoter were determined. Correlations between these BDNF measures and NLRP3-related genes were investigated. A significant relationship between BDNF mRNA expression and mean methylation was observed in control subjects but not in AD. In controls, significant correlations with both BDNF expression and mean BDNF methylation were observed for NLRP3, CASP1 and IL1B. These correlations were lost in the AD group, which also showed a significant correlation of KCNK13 expression with both BDNF measures, not seen in controls. This study indicates that the relationship between BDNF and NLRP3 activation, as measured by NLRP3 inflammasome components and proinflammatory cytokine products, is disrupted in AD. The contrary correlation emerging in AD between BDNF measures and KCNK13 expression, shown to be elevated in AD, indicates the possible relationship of this finding with BDNF dysfunction. These findings enhance our understanding of AD pathophysiology, demonstrating the importance of understanding the neuroinflammatory-neurotrophic balance in neurodegenerative processes. |
Journal of neural transmission (Vienna, Austria : 1996) | 2026 Oct 3 | PubMed |
| 07 |
Assessing AI Feasibility for Pain Evaluation in Hospitalized Cognitively Impaired Older Adults.
View abstractPURPOSE: The objectives for this study were to examine the acceptability and feasibility of using the artificial intelligence-driven application PainChek to identify pain within older adults with cognitive impairment in the inpatient setting within Ontario. DESIGN: A prospective cohort design was used. METHODS: Six nurses were recruited and completed standardized training. Following the recruitment and onboarding of nurse participants, 25 patient participants were enrolled and assessed using the application. Once patient data collection was complete, qualitative interviews with nursing participants were conducted. Descriptive statistics were used for patient and nurse participant data, and descriptive content analysis captured nurses' experiences using PainChek during the study. RESULTS: Participant demographics included 16% with delirium, 20% with cognitive impairment, and 64% with dementia. Average length of stay in the study was 7.8 days, with an average pain score while being assessed as mild pain. Thematic coding was conducted using the nursing metaparadigm as the guiding conceptual framework. Results were validated using member checking. CONCLUSIONS: Our study demonstrates that it is acceptable and feasible to use PainChek within the older adult hospital setting; however, additional research is warranted to evaluate its feasibility and scalability in real-world environments. |
Pain management nursing : official journal of the American Society of Pain Management Nurses | 2026 Oct 3 | PubMed |
| 08 | Improving care of dementia: Recent findings to improve person-centred diagnosis and treatment. | International psychogeriatrics | 2026 Oct 3 | PubMed |
| 09 |
Therapeutic potential of proline-rich peptide-1 (PRP-1) in counteracting amyloid-β-mediated cortical and hippocampal neurodegeneration in a rat model.
View abstractAlzheimer's disease (AD) is associated with amyloid β (Aβ) accumulation, neuronal metabolic dysfunction, and structural degeneration. This study compares the neurotoxic effects of Aβ25-35 and Aβ1-42 in the rat cerebral cortex and hippocampus and evaluates the neuroprotective potential of proline rich peptide 1 (PRP-1). Amyloid peptides were administered bilaterally into the lateral ventricles, followed by intramuscular PRP-1 at 0.1 mg/kg once daily for three weeks, beginning 24 h after amyloid administration. Neuronal metabolic activity was assessed by Ca2⁺ dependent acid phosphatase histochemistry with a lead capture reaction. Reaction intensity was quantified by densitometry as mean gray value (MGV), with lower values indicating greater reaction product accumulation and higher enzymatic activity. Both amyloid species disrupted cortical laminar organisation and altered enzymatic reactivity in the perikarya and dendrites of cortical pyramidal neurons, with Aβ1-42 causing greater structural disruption. When fields recorded with the same objective were compared, Aβ1-42 produced suppression of enzymatic activity in the hippocampus. CA1 pyramidal neurons showed the highest susceptibility, with confluent areas of reduced reactivity and interruption of the pyramidal cell layer. In the cortex, changes were restricted to the most severely damaged neurons. PRP-1 attenuated these alterations, preserved neuronal morphology, increased the number of reactive neurons, and enhanced enzymatic reactivity in both regions. Protection was greater in the hippocampus. These findings indicate that Aβ1-42 has greater neurotoxicity than Aβ25-35 and that PRP-1 reduces amyloid associated neuronal injury while supporting metabolic and structural recovery. PRP-1 merits further investigation as a candidate therapeutic agent for early amyloid associated neurodegeneration. |
Neuroscience | 2026 Oct 3 | PubMed |
| 10 |
A statistical framework for integrative imaging genomics with biclustering and ensemble penalized regression in Alzheimer's disease.
View abstractImaging genomics provides a powerful paradigm for decoding the complex interplay between molecular variation and brain functional phenotypes in neurodegenerative disorders. In this study, the molecular modality is specifically gene expression data rather than time-invariant genetic variants. However, statistically integrating these high-dimensional modalities remains challenging, as existing methods often rely on incomplete biological priors or overlook the latent modular structure of the data. To address this, we propose BRIDGE (Biclustering and ensemble penalized Regression for Integrative Data in Genomics and nEuroimaging), a unified statistical framework that synergistically integrates biclustering with ensemble penalized regression. Our approach proceeds in three interdependent stages: (1) accurate estimation of individual brain functional networks via sparse precision matrices; (2) data-driven discovery of regulatory modules-defined as subsets of gene expression features co-varying with subsets of brain connections-using a sparse biclustering algorithm; and (3) stable disease classification and biomarker identification via dimensionality reduction integrated with an ensemble penalized logistic regression model. Simulation studies demonstrate that BRIDGE outperforms ablation variants of the proposed framework and external competing benchmark methods in both feature selection performance and classification accuracy. In an application to the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, the framework achieved robust out-of-sample classification performance and uncovered biologically interpretable disease-related modules. These results highlight BRIDGE as a rigorous tool for integrative imaging genomics, capable of identifying pathogenic factors without reliance on a priori knowledge. |
NeuroImage | 2026 Oct 3 | PubMed |
| 11 |
Exercise, Glucose and Lactate Metabolism in Mild Cognitive Impairment: A Narrative Review.
View abstractMild cognitive impairment (MCI) is associated with cerebral glucose hypometabolism and an increased risk of progression to Alzheimer's disease (AD). Altered lactate metabolism may represent an additional component of this metabolic vulnerability. We propose the Dual-Fuel Hypothesis as a testable framework linking glucose-related metabolism with lactate-dependent energy and signaling pathways, while recognizing that this pathway has not been directly tested in MCI. This narrative review was guided by the SANRA framework. Structured screening was conducted specifically for randomized exercise-intervention studies in MCI, identifying 35 publications representing 29 independent cohorts. Evidence consistently supports impaired cerebral glucose metabolism in MCI due to AD, whereas alterations in lactate homeostasis and transport remain less clearly defined. Exercise improves systemic glucose utilization and increases circulating lactate, particularly during vigorous intensity aerobic and resistance exercise. Several trials reported favorable cognitive or neuroimaging outcomes, although larger or longer trials did not consistently show significant between-group cognitive benefits. No identified MCI exercise trial has concurrently measured exercise-induced lactate, cerebral substrate utilization, and cognition. |
International journal of sports medicine | 2026 Oct 3 | PubMed |
| 12 |
Systems-level bioinformatics analysis of hsa-miR-132-3p targets identifies a conserved neuroimmune regulatory module relevant to Alzheimer's disease.
View abstractAlzheimer's disease (AD) arises from converging neurodegeneration and neuroinflammation, yet post-transcriptional mechanisms linking these processes remain poorly defined. Hsa-miR-132-3p, a neuron-enriched microRNA consistently downregulated in AD, has emerged as a candidate integrator of synaptic plasticity and innate immune signaling. Targets of hsa-miR-132-3p were collected from five repositories (miRTarBase v10.0, DIANA-TarBase v9.0, ENCORI v3.0, miRWalk v3.0, miRDB v6.0) and integrated using multiMiR. Functional annotation used ShinyGO v0.81 (KEGG, GO-BP), with immune enrichment via MSigDB Hallmark, ImmPort, and InnateDB. High-confidence targets were defined by overlap with TargetScan conserved predictions and MalaCards AD genes. PPI networks were built with STRING v12.0/MCODE, and transcriptomic validation used GSE5281 hippocampal microarray data. Integration of five repositories identified 5429 non-redundant candidate targets, with significant enrichment in prefrontal cortex and CD33 + myeloid cell signatures (adjusted p < 0.05). Immune analyses highlighted TNFα/NF-κB, IL-6/JAK-STAT3, and interferon signaling overrepresentation. Intersection with TargetScan conserved predictions and MalaCards prioritized a 14-gene module (GSK3B, MAPK1, MAPK3, EP300, FOXO3, PIK3CA, PPP3CA, MAPT, EGR1, NR4A2, SLC30A6, ADCYAP1, SLC6A3, SV2A) defined by the convergence of experimentally supported target annotations, conserved TargetScan predictions, and AD-associated gene annotations. PPI mapping identified MAPK1, MAPK3, EP300, MAPT, and EGR1 as a central interaction module associated with inflammatory signaling and tau-associated processes. Hippocampal transcriptomic analysis provided exploratory evidence of overlap between candidate hsa-miR-132-3p targets and AD-associated differentially expressed genes (KDM4B,CBX3 and MORF4L2). This analysis nominates hsa-miR-132-3p as a candidate post-transcriptional regulator potentially linking neuronal stress, tau pathology, and innate immune signaling in AD. The 14-gene module provides a hypothesis-generating framework for cell-type-resolved experimental validation. |
Computational biology and chemistry | 2026 Oct 1 | PubMed |
| 13 |
Mechanistic exploration of 4-bromobenzyloxy-1,2,3-triazole derivatives as dual cholinesterase inhibitors: Kinetic, molecular dynamics, and halogen-contact insights.
View abstractAcetylcholinesterase (AChE) and butyrylcholinesterase (BChE) regulate cholinergic neurotransmission, and their partial inhibition is an established symptomatic strategy in Alzheimer's disease; clarifying how individual ligands engage these enzymes is therefore central to inhibitor design. To probe these cholinesterase-ligand interaction mechanisms, a series of eight 4-bromobenzyloxy-1,2,3-triazole derivatives (10a-10 h) was synthesized and evaluated as AChE and BChE inhibitors. All compounds displayed concentration-dependent inhibition of both enzymes at micromolar concentrations (IC = 1.52-4.05 µM for AChE and 2.18-7.83 µM for BChE). Compound 10e was the most effective AChE inhibitor and compound 10 g the most effective BChE inhibitor. Detailed kinetic analysis, with inhibition constants obtained by global nonlinear regression and the mechanism assigned by Akaike-based model selection, revealed predominantly mixed-type inhibition (K = 0.95 µM, α = 2.10 for 10e-AChE; K = 1.55 µM, α = 2.14 for 10g-BChE) and predominantly noncompetitive inhibition for 10d, indicating simultaneous or allosteric engagement of the catalytic and peripheral sites. These mechanisms were corroborated by molecular docking, 100 ns molecular dynamics simulations, and MM/GBSA analysis, and the docking binding energies correlated closely with experimental potency across the series (r > 0.99). Geometric analysis showed that 10 g engages the BChE gorge through an additional short, non-linear C-F···O contact rather than a classical halogen bond. In silico DFT, ADMET, and toxicity predictions indicated generally drug-like, CNS-penetrant profiles for most derivatives, although 10d was flagged for potential genotoxic liability and deprioritized. Collectively, these findings characterize the dual cholinesterase inhibitory activity of the 4-bromobenzyloxy-1,2,3-triazole scaffold and position 10e and 10 g as effective lead-like compounds warranting further optimization. |
Computational biology and chemistry | 2026 Sep 30 | PubMed |
| 14 |
Cortex-grounded diffusion models for brain image generation.
View abstractSynthetic neuroimaging data can mitigate critical limitations of real-world datasets, including the scarcity of rare phenotypes, domain shifts across scanners, and insufficient longitudinal coverage. However, existing generative models largely rely on weak conditioning signals, such as labels or text, which lack anatomical grounding and often produce biologically implausible outputs. To this end, we introduce Cor2Vox, a cortex-grounded generative framework for brain magnetic resonance image (MRI) synthesis that ties image generation to continuous structural priors of the cerebral cortex. It leverages high-resolution cortical surfaces to guide a 3D shape-to-image Brownian bridge diffusion process, enabling topologically faithful synthesis and precise control over underlying anatomies. To support the generation of new, realistic brain shapes, we developed a large-scale statistical shape model of cortical morphology derived from over 33,000 UK Biobank scans. We validated the fidelity of Cor2Vox based on traditional image quality metrics, advanced cortical surface reconstruction, and whole-brain segmentation quality, outperforming many baseline methods. Across three applications, namely (i) anatomy-guided synthesis, (ii) simulation of progressive gray matter atrophy, and (iii) harmonization of in-house frontotemporal dementia scans with public datasets, Cor2Vox preserved fine-grained cortical morphology at the sub-voxel level. Notably, the proposed model exhibits inherent robustness to variations in cortical geometry and unseen dementia phenotypes without retraining, paving the way for disease progression modeling and robust data augmentation in rare neurodegenerative disorders. |
Medical image analysis | 2026 Sep 29 | PubMed |
| 15 |
Improvement of Autonomic and Cognitive Dysfunction by Memantine in a Patient with Dementia with Lewy Bodies and Cardiac Conduction Defect: A Case Report.
View abstractPURPOSE: Dementia with Lewy bodies (DLB) ranks among the most frequent neurodegenerative cognitive disorders, characterized by multi-domain deficits including autonomic dysfunction and fluctuating cognition. Current management remains symptomatic, particularly in patients with comorbidities limiting standard therapies. SUMMARY: We report a 73-year-old female with DLB and pre-existing cardiac conduction defects, rendering cholinesterase inhibitors contraindicated. Following memantine (10 mg/day) treatment over three months, changes in autonomic and cognitive measures were observed. Heart rate variability parameters increased, accompanied by a reduction in SCOPA-AUT score and an increase in MMSE score. No adverse events were observed. CONCLUSION: These findings suggest memantine as a potential therapeutic alternative for DLB patients with autonomic fragility. |
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists | 2026 Oct 3 | PubMed |
| 16 |
Collagen Triple Helix Repeat Containing 1 (CTHRC1) in the Nervous System: Expression, Signaling Mechanisms, and Functional Implications.
View abstractCollagen triple helix repeat containing 1 (CTHRC1) is a secreted extracellular matrix (ECM)-associated protein involved in tissue remodeling, fibrosis, and cancer, but its functions in the nervous system remain incompletely defined. Evidence from peripheral nerve, brain tumor, neurodegeneration, and regeneration models suggests that CTHRC1 may exert context-dependent effects across neural and stromal cell populations. In Schwann cells, CTHRC1 regulates proliferation, migration, and the timing of myelination, whereas in glioma it promotes invasive behavior and treatment-resistant phenotypes. Human cortical proteomics, mouse-model studies, systems genetics, and a neuronal cell model associate CTHRC1 with Alzheimer's disease-related phenotypes, although bulk tissue does not identify the cellular source and a small cerebrospinal fluid cohort showed no significant change. Temporally resolved single-cell analysis in zebrafish identified a transient cthrc1a-expressing fibroblast state required for coordinated inflammatory dynamics during regeneration; an equivalent mammalian mechanism has not been established. Evidence connecting CTHRC1 to synaptic regulation, neuroprotection, Parkinson's disease, and cerebrovascular repair is still preliminary. Wnt, TGF-β/Smad, PI3K/AKT, and MAPK/ERK pathways provide candidate mechanisms, but many were characterized outside normal neural cells. This review critically evaluates the evidence by model and cell type and discusses biomarker and therapeutic prospects, including delivery, specificity, and safety constraints. |
Journal of molecular neuroscience : MN | 2026 Oct 3 | PubMed |
| 17 |
Evaluation of novel targeted small-molecule therapeutics in desmoplastic small round cell tumor (DSRCT) cells.
View abstractPURPOSE: Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma associated with an extremely poor prognosis. This study evaluates the therapeutic potential of targeted, non-DNA-damaging small-molecule inhibitors in an in vitro DSRCT model. METHODS: We characterized the genomic architecture of the JN-DSRCT-1 cell line using fluorescence in situ hybridization (FISH) and sequencing of the tumor suppressor TP53. In silico analysis was performed to identify shared vulnerabilities between DSRCT and Ewing sarcoma (ES). Using flow cytometry (assessing cell death, mitochondrial membrane potential loss, caspase-3 activity, and cell cycle distribution) and quantitative real-time PCR (qPCR), we systematically evaluated a small-molecule screening panel. The panel targeted chromatin acetylation (entinostat, vorinostat, tenovin-1), p53 pathway activity (RETRA, nutlin-3, RITA), receptor tyrosine kinases (imatinib), and transcription factor DNA-binding dynamics (mithramycin). RESULTS: JN-DSRCT-1 cells exhibited complex aneuploidy, and we confirmed the presence of the pathognomonic balanced EWSR1::WT1 translocation. Histone deacetylase inhibitors (entinostat, vorinostat) and nutlin-3 (an MDM2 antagonist) triggered robust intrinsic apoptosis and upregulated p53 target genes (p21, PUMA, and NOXA). Mithramycin demonstrated high cytotoxicity, whereas imatinib was ineffective. Pan-caspase inhibition using z-VAD-FMK rescued cells from entinostat-, vorinostat-, nutlin-3-, and mithramycin-induced death, but failed to protect against tenovin-1, RITA, or RETRA, indicating the activation of caspase-independent cell death pathways. CONCLUSION: DSRCT cells display high sensitivity to histone deacetylase inhibition, p53 pathway activation, and mithramycin. Among these, histone deacetylase inhibition alone or in combination with other small molecule drugs represents a particularly promising strategy for overcoming DSRCT cell survival. |
Journal of cancer research and clinical oncology | 2026 Oct 3 | PubMed |
| 18 |
Multimodal neuroimaging in dementia and neurodegenerative disorders: complementary roles of clinically available nuclear medicine and MRI in the era of disease-modifying therapies.
View abstractThe introduction of anti-amyloid-β antibody therapies has fundamentally changed the clinical landscape of dementia, shifting the role of neuroimaging from diagnosis toward therapeutic decision-making. Amyloid positron emission tomography (PET) has become essential for confirming amyloid pathology and determining treatment eligibility. However, amyloid deposition is frequently observed in cognitively normal elderly individuals and in non-Alzheimer neurodegenerative disorders, indicating that amyloid status alone is insufficient to explain clinical symptoms. In this context, imaging modalities reflecting neurodegeneration, including structural magnetic resonance imaging (MRI) and functional imaging such as F-FDG-PET and brain perfusion single-photon emission computed tomography (SPECT), remain important for assessing disease severity and functional impairment. Furthermore, discrepancies between imaging biomarkers-such as the presence of neurodegeneration without amyloid pathology in cases clinically suspected of Alzheimer's disease, and atypical imaging patterns-are commonly encountered in clinical practice and may reflect underlying pathological heterogeneity. A multimodal imaging approach that integrates multiple biomarkers provides complementary information and may improve diagnostic accuracy and clinical interpretation. In addition, other imaging modalities, including dopamine transporter (DAT) imaging and cardiac sympathetic imaging, can contribute to the evaluation of non-Alzheimer pathologies. This review summarizes the current roles of clinically available multimodal imaging in dementia, with a focus on nuclear medicine and MRI, highlighting their complementary value and clinical implications in the era of disease-modifying therapies. |
Japanese journal of radiology | 2026 Oct 3 | PubMed |
| 19 |
Sensory gamma entrainment in older adults with or without cognitive impairment: a systematic review and exploratory meta-analysis.
View abstractGamma entrainment using sensory stimulation (GENUS) is a noninvasive approach under investigation in older adults with and without cognitive impairment, including Alzheimer's disease; however, human evidence remains scattered across structural, functional, biomarker, electrophysiological, and cognitive domains. We searched PubMed, Embase, Scopus, and Web of Science for English-language articles published from January 2016 to December 2025, following PRISMA 2020 guidelines and a retrospectively registered PROSPERO protocol. Eligible studies evaluated non-invasive sensory gamma-frequency stimulation in adults aged 60 years, including Alzheimer's disease-spectrum and cognitively normal older adults, with quantitative outcomes reported in at least one relevant domain. Narrative synthesis was the primary approach, supplemented by an exploratory random-effects meta-analysis of hippocampal and ventricular volume change. Eight studies were included, spanning single-session to 6-month interventions. Findings were directionally favorable across domains but derived from small, heterogeneous studies with nonoverlapping outcomes. Fluid biomarker evidence was limited to exploratory immune-related findings from a single uncontrolled study. Controlled structural studies suggested possible attenuation of hippocampal atrophy, ventricular enlargement, and white matter decline. Functional connectivity findings suggested possible preservation of connectivity in Alzheimer's disease-relevant networks. Electroencephalography studies supported target engagement, with entrainment strength and propagation varying according to stimulation parameters and individual characteristics. Cognitive findings from small exploratory studies did not establish a consistent benefit. Exploratory pooled effects for ventricular and hippocampal volume change were favorable but not robust to conservative sensitivity analysis. Human evidence for GENUS is promising but preliminary and hypothesis-generating; larger, adequately powered, standardized trials are needed before firm efficacy conclusions can be drawn. |
GeroScience | 2026 Oct 3 | PubMed |
| 20 |
The role of social white matter tracts in susceptibility to phishing in aging.
View abstractVulnerability to fraud and financial exploitation among older adults is an increasing public health concern. Growing evidence supports that cognitive and socioemotional changes with age contribute to greater exploitation risk among older adults, while the neural mechanisms of heightened susceptibility to deception in aging are not well understood. Of note, white matter tracts are particularly impacted in aging and are likely implicated in deception detection. This study, for the first time, examined the extent to which age-related differences in white matter pathways subserving social cognition mediated susceptibility to email phishing, a potent, fast-evolving Internet deception threat. Fifty-one younger (21.82 ± 3.47 years) and 46 cognitively healthy older (68.87 ± 6.56 years) adults underwent diffusion-weighted imaging and completed the ecologically-valid PHishing Internet Task (PHIT), which provides a behavioral measure of real-life susceptibility to email phishing. Deterministic tractography-generated a priori tracts of interest included the cingulum, uncinate fasciculus (UF), anterior thalamic radiation (ATR), and superior longitudinal fasciculus-collectively referred to as "social white matter." White matter integrity metrics (i.e., mean diffusivity [MD] and fractional anisotropy [FA]) were extracted from these tracts. Regression-based mediation analyses controlling for sex, education, general cognition, and global MD and FA (separately) showed that both increased right ATR MD and decreased left UF FA partially mediated the effects of age group on phishing susceptibility (higher PHIT scores with greater age). These findings advance a social white matter-based account of age-related exploitation risk, shedding light on the neurobiology underlying social decision-making deficits in aging. |
GeroScience | 2026 Oct 3 | PubMed |
| 21 |
The immunoproteasome in Alzheimer's disease: a dual regulator of tau pathology and microglial senescence.
View abstractAlzheimer's disease (AD) is characterized by progressive cognitive decline driven by the convergence of tauopathy, impaired proteostasis, and chronic neuroinflammation. Emerging evidence identifies the immunoproteasome (iP), particularly the β5i/LMP7 subunit, as a central regulator linking these pathological processes. Unlike the constitutive proteasome, the iP is markedly induced in microglia, neurons, and astrocytes under inflammatory conditions through interferon-γ and NF-κB signaling. This review discusses the dual and context-dependent role of the iP in AD pathogenesis. In microglia, chronic iP activation promotes degradation of NRF2, leading to oxidative stress, NLRP3 inflammasome activation, and the development of a senescence-associated secretory phenotype that exacerbates neuroinflammation and tau propagation. In neurons, moderate iP activity facilitates the clearance of phosphorylated tau; however, sustained overactivation generates aggregation-prone tau fragments that enhance trans-synaptic tau spreading. We further highlight the cross-talk between the iP and autophagy pathways through TFEB and p62/SQSTM1 signaling and discuss how gut microbiota-derived inflammatory mediators may prime central iP activation through the gut-brain axis. Importantly, recent preclinical studies support the concept of partial immunoproteasome modulation rather than complete inhibition, with selective LMP7 targeting restoring proteostatic balance, reducing microglial senescence, and attenuating tau pathology. Collectively, the iP emerges as a promising immunopharmacological target and a potential therapeutic rheostat in AD. |
Inflammopharmacology | 2026 Oct 3 | PubMed |
| 22 |
Stem cells and derived growth factors in Alzheimer's disease: mechanistic insights and translational perspectives.
View abstractAlzheimer's disease (AD) is a significant healthcare concern due to the complex interactions between amyloid-β accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and progressive neuronal death. Stem-cell-based therapies have demonstrated potential to treat this complex condition through immunomodulation, trophic support, and neuroregeneration. Beyond direct cell replacement, stem-cell-derived growth factors have important therapeutic functions by providing strong neurotrophic and cytoprotective effects. These bioactive compounds improve neuronal survival, restore synaptic plasticity, and reduce inflammatory cascades that accelerate the course of AD. Important growth factors that support increased neural resilience, cholinergic preservation, synaptic strengthening, and mitochondrial stabilization include BDNF, NGF, and IGF-1. The current study synthesizes molecular knowledge and new clinical data to assess the translational potential of stem cells and their growth-factor secretome. According to preclinical research, neural stem cells (NSCs) increase synaptic density and maintain cholinergic integrity in APP/PS1 mice, while mesenchymal stem cells (MSCs) lower amyloid burden, inhibit microglial activation, and improve memory. The stem-cell secretome offers a significant therapeutic benefit. BDNF increases synaptic plasticity, NGF promotes cholinergic survival, and IGF-1 improves mitochondrial function and diminishes oxidative stress and tau-mediated toxicity. However, significant obstacles impede clinical advancement. Therapeutic stability is limited by the risks of tumorigenicity, poor long-term engraftment, immunological rejection, and irregular blood-brain barrier penetration. Major challenges persist, such as manufacturing inconsistency, scalability limitations, and difficulties attaining controlled growth-factor dosing. To advance stem-cell-based techniques for significant AD alterations, these hurdles must be overcome by biomaterial optimization, modified secretomes, and standardized production platforms. |
Inflammopharmacology | 2026 Oct 3 | PubMed |
| 23 |
The Therapeutic Potential of MicroRNAs Delivered By Mesenchymal Stem Cells in Parkinson's Disease, Alzheimer's Disease, and Stroke: A Systematic Review of Preclinical Studies.
View abstractPopulation aging has led to a substantial increase in the prevalence of neurological disorders, including Parkinson's disease (PD), Alzheimer's disease (AD), and stroke. As current therapeutic strategies are largely limited to symptomatic management, the identification of disease-modifying treatments remains a major unmet clinical need. Mesenchymal stem cells (MSCs) and MSCs-derived microRNAs (miRNAs) have emerged as promising therapeutic candidates for these conditions. A systematic literature search was conducted in the PubMed and Scopus databases in accordance with the PRISMA guidelines. The aim was to synthesize the available evidence regarding the effects of MSCs-derived miRNAs on cellular processes, including apoptosis, proliferation, inflammation, oxidative stress, and motor function in experimental models of PD, AD, and stroke. Risk of bias was assessed using the SYRCLE Risk of Bias tool for animal intervention studies and the modified OHAT Risk of Bias Rating Tool (mOHAT). A total of 37 preclinical studies were included in the review: 9 focused on PD, 10 on AD, and 18 on stroke. The synthesized evidence indicates that specific MSCs-derived miRNAs, particularly miR-133b, miR-146a, miR-17-92, and miR-223, exert significant neuroprotective effects. These miRNAs actively modulate gene expression, attenuate neuroinflammation and apoptosis, and reduce the accumulation of disease-specific pathological markers, including α-synuclein and amyloid-β (Aβ). Furthermore, targeted delivery of these miRNAs was associated with improved motor and cognitive outcomes across the evaluated animal models. MSCs-derived miRNAs demonstrate considerable therapeutic potential for the treatment of neurodegenerative diseases and stroke through the modulation of multiple pathological pathways. However, as the current evidence is derived exclusively from in vitro and animal studies, future research should focus on the development of safe, standardized, and reproducible protocols to facilitate the translation of these findings into human clinical trials. The review was registered in the Open Science Framework (OSF): https://osf.io/cxt9b . |
Molecular neurobiology | 2026 Oct 3 | PubMed |
| 24 |
Exploring the role of glymphatic system in Alzheimer's disease with insights from MRI-based studies: a systematic review.
View abstractBACKGROUND: The glymphatic constitutes a crucial neurophysiological mechanism for the clearance of interstitial solutes and neurotoxic metabolites from the central nervous system. Dysfunction within this pathway is increasingly implicated in the etiopathogenesis of neurodegenerative diseases, notably Alzheimer's disease (AD). Advanced magnetic resonance imaging (MRI) modalities, such as diffusion tensor image analysis along the perivascular space (DTI-ALPS), have emerged as non-invasive, in vivo approaches quantifying glymphatic transport efficacy and its association with cognitive decline and AD progression. METHODS: This systematic review was conducted in adherence with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. and systematic literature retrieval was executed across PubMed, Cochrane, and Scopus databases, targeting studies that employed MRI-based metrics to assess glymphatic functionality in the context of AD. RESULTS: A total of 35 studies fulfilled the inclusion criteria. AD patients exhibited significantly reduced DTI-ALPS indices, correlating with elevated enlarged perivascular space (ePVS) volumes, neurocognitive deterioration, and cerebral atrophy. Notably ePVSs enlargement emerged as a surrogate marker of glymphatic dysfunction and a predictor of MCI-to-AD conversion. However, amyloid PET correlations exhibited inter-study heterogeneity. CONCLUSIONS: MRI derived biomarkers, particularly DTI-ALPS index and ePVSs analysis, demonstrate high potential as surrogate indicators of glymphatic impairment in AD. These findings underscore their diagnostic and prognostic value, warranting harmonization of imaging protocols and longitudinal investigations to establish their translational utility in clinical biomarker frameworks. CLINICAL RELEVANCE STATEMENT: MRI biomarkers of glymphatic dysfunction provide valuable insights into Alzheimer's disease pathophysiology and progression. These imaging markers may enhance early diagnosis, monitor disease progression, and evaluate treatment efficacy in AD. |
Neuroradiology | 2026 Oct 3 | PubMed |
| 25 |
Return of Research Results to Participants in Longitudinal Cohort Studies in Health Research: Findings From 24 Cohorts of the Amsterdam Cohort Hub.
View abstractBACKGROUND: Returning research results to participants is increasingly recognised as part of participant-centred health research. How this is implemented in longitudinal cohort studies is not yet well characterised. This study aims to provide a descriptive overview of current result return practices across diverse cohort studies in the Netherlands. METHODS: Drawing on the Amsterdam Cohort Hub, an infrastructure of population-based and patient-based cohorts in the Netherlands, representatives of 24 affiliated cohort studies completed a structured questionnaire administered via individual interviews. The questionnaire covered what results are returned, to whom, when and how. Individual-level and group-level return were distinguished. Cohorts also reported on motivations for returning results and barriers encountered in doing so. Data were summarised descriptively using frequencies. RESULTS: Individual-level results beyond incidental findings were returned by 15 cohorts (65.2%), while group-level results were returned by 23 cohorts (96%). Individual-level return primarily involved physical and laboratory measures or was embedded in routine clinical care. Group-level results were mainly shared through newsletters. Practices varied by cohort type and were shaped by ethical considerations and practical constraints. Concerns about participant misinterpretation and limited resources were the most reported barriers. CONCLUSION: Return of research results is widely practised across cohort studies, but varies considerably in approach, shaped by ethical considerations, perceived communication risks, and financial and practical constraints. This descriptive overview of current practices may serve as a starting point for cohorts seeking to reflect on or develop their own result return procedures. Future research should examine the effects of various forms of result return on participant engagement and retention, as well as the role of participant preferences in shaping these practices. PATIENT OR PUBLIC CONTRIBUTION: This study includes a descriptive inventory of patient and public involvement in longitudinal cohort studies, in the form of result return practices. The findings are directly relevant to research participants, as they concern how cohort studies communicate research results to the people who contribute their data. The results may inform how cohorts develop and improve their participant communication strategies in the future. |
Health expectations : an international journal of public participation in health care and health policy | 2026 Oct | PubMed |
| 26 | Undiagnosed dementia in underserved African American populations: Missed opportunities for care. | International psychogeriatrics | 2026 | Scholar |
| 27 | Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation. | Alzheimer's research & therapy | 2026 | Scholar |
| 28 | Biopsychosocial risk factors for Alzheimer’s disease and related dementias in UK immigrants from the Middle East and North Africa (MENA) | medRxiv | 2026 | Scholar |
| 29 | Decreased Length of Locus Coeruleus Norepinephrine Axons and Increased Amyloid Beta Pathology in Male APP/PS1 Mice During Protracted Abstinence From Alcohol | Neurotoxicity Research | 2026 | Scholar |

